Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 May;46(2):327-341.
doi: 10.1016/j.rdc.2020.01.009.

Axial Psoriatic Arthritis: A Distinct Clinical Entity in Search of a Definition

Xabier Michelena  1 , Denis Poddubnyy  2 , Helena Marzo-Ortega  3
Affiliations
Review

Axial Psoriatic Arthritis: A Distinct Clinical Entity in Search of a Definition

Xabier Michelena et al. Rheum Dis Clin North Am. 2020 May.

Abstract

Axial involvement in psoriatic arthritis is a well-recognized manifestation with a prevalence between 12.5% and 78%. This huge heterogeneity is due to the different criteria used by authors to define psoriatic arthritis with axial involvement combining clinical features with radiographic evidence of disease. Specific genetic and clinical attributes of axial psoriatic arthritis might differentiate it from axial spondyloarthritis with concurrent skin psoriasis. Few studies address the specific management. The purpose of this review is to acknowledge the current understanding of axial involvement in psoriatic arthritis and highlight the need for a definition to facilitate research and clinical recognition.

Keywords: Axial involvement; Axial psoriatic arthritis; Axial spondyloarthritis; Psoriatic arthritis; Psoriatic spondylitis.

PubMed Disclaimer

Conflict of interest statement

Disclosure X. Michelena has received speaking fees from UCB, Novartis, and Sanofi-Genzyme. D. Poddubnyy: research grants from AbbVie, Lilly, MSD, Novartis, and Pfizer. Consultancy/speaker fees from AbbVie, BMS, Celgene, Janssen, Lilly, MSD, Novartis, Pfizer, Roche, and UCB; H. Marzo-Ortega: research grants from Janssen and Novartis. Consultancy/Speaker from AbbVie, Celgene, Eli-Lilly, Janssen, Novartis, Takeda, UCB.

Publication types